NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Puma Biotechnology, Inc. (PBYI) Stock Analysis

Puma Biotechnology, Inc. (PBYI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PBYI

$9.55

+$0.14 (+1.49%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PBYI with… →

PBYI Key Statistics

As of Sep 4, 2026
Trading
Open
$9.40
Previous Close
$9.41
Day's Range
9.31–9.64
52-Week Range
4.30–9.74
Volume
185.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.23
Valuation
Market Cap
$492.97M
P/E Ratio
18.73
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
27.29
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.13
EPS (ttm)Profit attributable to each share over the last twelve months.
0.51
Financials (FY)
Revenue (FY)
$228.37M−0.91%
Net Income (FY)
$31.11M+2.75%
Profit marginThe share of revenue left as profit after all costs and taxes.
11.55%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
51.62M
1-Year Return
+86.89%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
331.55K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PBYI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+60.50%
2025+95.08%
2024−29.56%
2023+2.36%
2022+39.14%
2021−70.37%
2020+17.26%
2019−57.00%
2018−79.41%
2017+221.99%
2016 (partial year)−33.32%

As of September 4, 2026.

PBYI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$228.37M$31.11M13.6%
2024$230.47M$30.28M13.1%
2023$235.64M$21.59M9.2%
2022$228.03M$2.00K0.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$228.37M$170.21M$37.30M$31.11M13.6%
2024$230.47M$166.06M$30.97M$30.28M13.1%
2023$235.64M$172.96M$32.64M$21.59M9.2%
2022$228.03M$172.94M$30.72M$2.00K0.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PBYI Valuation vs Biotechnology Median

Median of 656 stocks
MetricPBYIBiotechnology medianvs median
P/E18.7312.5749% above
P/S ratio2.1315.260.1x the median
Profit margin11.55%0.00%11.6 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Puma Biotechnology, Inc. (PBYI) at $492.97M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 179.

The most recent close on file for PBYI is $9.55, dated September 4, 2026. That is +$0.14 (+1.49%) against the previous close. The 52-week range on file runs from $4.30 to $9.74. The latest close sits 122.09% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $228.37M. That is −0.91% against the prior fiscal year, when revenue was $230.47M. Net income for the same year was $31.11M. That is +2.75% against the prior fiscal year. Profit margin runs at 11.55%. That is 11.6 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 0.51.

Across the 4 fiscal years on file, revenue moves from $228.03M in 2022 to $228.37M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

PBYI trades at a trailing price-to-earnings ratio of 18.73. That is 49.01% above the Biotechnology median of 12.57. On forward earnings the ratio is 27.29. The price-to-sales ratio is 2.13. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +86.89%. Measured over 10 years, that is −16.43% a year compounded. The reported beta is 1.23. Annualized volatility over the trailing 10 years is 80.09%.

Growth & Income

The record shows no dividend for PBYI.

Across the complete calendar years on file, 2017 returned +221.99% and 2018 returned −79.41%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is +60.50%.

Peer Comparison

Puma Biotechnology, Inc. (PBYI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Puma Biotechnology, Inc. PBYI $492.97M 18.7
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Puma Biotechnology, Inc. trades at a P/E of 18.7.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Puma Biotechnology, Inc.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Visit website →